High-dose therapy with the combination drug trimethoprim-sulfamethoxazole for the treatment of patients with Pneumocystis carinii pneumonia (PCP) is usually contraindicated in trimethoprim-sulfamethoxazole–intolerant patients with acquired immunodeficiency syndrome (AIDS). However, clinicians may have to reintroduce trimethoprim-sulfamethoxazole at high dosages to treat these patients with PCP. In those circumstances, prescribing drugs such as corticosteroids, which will decrease the risk of adverse cutaneous reaction, is desirable. Corticosteroids significantly reduced the incidence of adverse reaction to trimethoprim-sulfamethoxazole during treatment of patients with AIDS-associated PCP in 4 studies.1-4
Iborra C, Jouan M, Baril L, Katlama C, Bricaire F, Caumes E. High-Dose Trimethoprim-Sulfamethoxazole Therapy With Corticosteroids in Previously Intolerant Patients With AIDS-Associated Pneumocystis carinii Pneumonia. Arch Dermatol. 1999;135(3):350–351. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-3-dlt0399
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: